Hedge Fund - Rhenman & Partners Asset Management
Biomarin Pharmaceutical Inc (BMRN)
Holding History Records
| No. | Filing Period | Value | % of Portfolio | Number of Shares | Avg. Quarterly Share Price |
|---|---|---|---|---|---|
| 1 | 2025 - Q1 (2025-03-31) | $18,732,850 | 2.15% | 265,000 | $67.28 |
| 2 | 2024 - Q4 (2024-12-31) | $16,473,450 | 1.69% | 250,623 | $66.98 |
| 3 | 2024 - Q3 (2024-09-30) | $25,620,705 | 2.07% | 364,500 | $83.59 |
| 4 | 2024 - Q2 (2024-06-30) | $20,705,995 | 1.98% | 251,500 | $83.25 |
| 5 | 2024 - Q1 (2024-03-31) | $20,743,250 | 1.96% | 237,500 | $89.52 |
| 6 | 2023 - Q4 (2023-12-31) | $27,238,650 | 2.72% | 282,500 | $88.47 |
| 7 | 2023 - Q3 (2023-09-30) | $33,622,400 | 3.62% | 380,000 | $88.98 |
| 8 | 2023 - Q2 (2023-06-30) | $32,938,400 | 3.47% | 380,000 | $94.11 |
| 9 | 2023 - Q1 (2023-03-31) | $21,440,250 | 2.35% | 225,000 | $103.67 |
| 10 | 2022 - Q4 (2022-12-31) | $26,286,460 | 2.74% | 254,000 | $93.88 |
| 11 | 2022 - Q3 (2022-09-30) | $20,531,000 | 2.14% | 237,000 | $89.04 |
| 12 | 2022 - Q2 (2022-06-30) | $11,602,000 | 1.31% | 140,000 | $79.62 |
| 13 | 2022 - Q1 (2022-03-31) | $16,962,000 | 1.67% | 220,000 | $83.67 |
| 14 | 2021 - Q4 (2021-12-31) | $23,606,000 | 1.56% | 265,000 | $82.51 |
| 15 | 2021 - Q3 (2021-09-30) | $18,550,000 | 1.3% | 240,000 | $78.90 |
| 16 | 2021 - Q2 (2021-06-30) | $13,350,000 | 0.9% | 160,000 | $79.27 |
| 17 | 2021 - Q1 (2021-03-31) | $13,592,000 | 0.94% | 180,000 | $81.69 |
| 18 | 2020 - Q4 (2020-12-31) | $44,722,000 | 3.64% | 510,000 | $79.28 |
| 19 | 2020 - Q3 (2020-09-30) | $56,630,000 | 5.03% | 744,354 | $101.18 |
| 20 | 2020 - Q2 (2020-06-30) | $23,435,000 | 2.53% | 190,000 | $99.39 |
| 21 | 2020 - Q1 (2020-03-31) | $15,619,000 | 2.18% | 184,845 | $86.16 |
| 22 | 2019 - Q4 (2019-12-31) | $17,756,000 | 1.94% | 210,000 | $75.53 |
| 23 | 2019 - Q3 (2019-09-30) | $19,579,000 | 2.45% | 290,491 | $77.02 |
| 24 | 2019 - Q2 (2019-06-30) | $24,098,000 | 2.65% | 281,349 | $85.55 |
| 25 | 2018 - Q4 (2018-12-31) | $15,033,000 | 1.71% | 176,549 | $95.13 |
| 26 | 2018 - Q3 (2018-09-30) | $25,682,000 | 2.57% | 264,849 | $99.82 |
| 27 | 2018 - Q2 (2018-06-30) | $22,594,000 | 2.31% | 239,849 | $87.57 |
| 28 | 2018 - Q1 (2018-03-31) | $16,607,000 | 2.04% | 204,849 | $85.82 |
| 29 | 2017 - Q4 (2017-12-31) | $12,470,000 | 1.68% | 139,849 | $86.95 |
| 30 | 2017 - Q3 (2017-09-30) | $16,748,000 | 2.13% | 179,949 | $88.36 |
| 31 | 2017 - Q2 (2017-06-30) | $17,192,000 | 2.46% | 189,300 | $90.98 |
| 32 | 2017 - Q1 (2017-03-31) | $10,973,000 | 1.73% | 125,000 | $88.96 |
| 33 | 2016 - Q4 (2016-12-31) | $4,142,000 | 0.79% | 50,000 | $86.00 |
| 34 | 2016 - Q3 (2016-09-30) | $12,952,800,000 | 2.05% | 140,000 | $94.17 |
| 35 | 2016 - Q2 (2016-06-30) | $11,670,000 | 2.07% | 150,000 | $85.01 |
| 36 | 2016 - Q1 (2016-03-31) | $15,671,000 | 3.11% | 190,000 | $81.36 |
| 37 | 2015 - Q4 (2015-12-31) | $12,362,000 | 1.86% | 118,000 | $104.42 |
The displayed share prices are average quarterly stock market prices.